Da	te: Mar. 3 <sup>rd</sup> , 2022	-	
Yo	ur Name: Na Li		
Ma	nuscript Title: Inhibite	ory effects of LOXL2 knock	down on cellular functions of liver cancer stem cells
Ma	nuscript number (if known)	: TCR-22-298_	
In t	the interest of transparency	, we ask you to disclose al	I relationships/activities/interests listed below that are
rel	ated to the content of your	manuscript. "Related" me	ans any relation with for-profit or not-for-profit third
pa	rties whose interests may be	e affected by the content o	of the manuscript. Disclosure represents a commitment
to	transparency and does not i	necessarily indicate a bias.	If you are in doubt about whether to list a
rel	ationship/activity/interest,	it is preferable that you do	) so.
Th	e following questions apply	to the author's relationship	ps/activities/interests as they relate to the <u>current</u>
<u>ma</u>	nuscript only.		
			<u>defined broadly</u> . For example, if your manuscript pertains
		· •	all relationships with manufacturers of antihypertensive
me	dication, even if that medic	ation is not mentioned in	the manuscript.
	-		d in this manuscript without time limit. For all other items,
the	e time frame for disclosure is	s the past 36 months.	
		Name all entities with	Specifications/Comments
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		whom you have this	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
1	All support for the present	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding,	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone	(e.g., if payments were made to you or to your institution)  I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone  Time frame: past	(e.g., if payments were made to you or to your institution)  I planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone	(e.g., if payments were made to you or to your institution)  I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone  Time frame: past	(e.g., if payments were made to you or to your institution)  I planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone  Time frame: past	(e.g., if payments were made to you or to your institution)  I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone  Time frame: pastXNone	(e.g., if payments were made to you or to your institution)  I planning of the work

Consulting fees

X\_\_None

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	x	
	, , , , , , , , , , , , , , , , , , ,		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNOTIE	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dاح	ease summarize the above co	onflict of interest in the fol	lowing hox:
ric	.asc sammanze the above to		ioming box.
	None.		

Da	te: Mar. 3 <sup>rd</sup> , 2022	_	
Yo	ur Name: Huan Gu		
Ma	nuscript Title: Inhibit	ory effects of LOXL2 knocl	kdown on cellular functions of liver cancer stem cells
Ma	nuscript number (if known)	): TCR-22-298_	
In t	the interest of transparency	v. we ask you to disclose a	Il relationships/activities/interests listed below that are
		·	eans any relation with for-profit or not-for-profit third
	-	-	of the manuscript. Disclosure represents a commitment
-			. If you are in doubt about whether to list a
	ationship/activity/interest,	•	•
ıeı	ationship/activity/interest,	it is preferable that you u	0 30.
TL	- fallandaa amakiana amaki	* - *	ine /estivities /interpolate as they relate to the commant
		to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
ma	nuscript only.		
			defined broadly. For example, if your manuscript pertains
		· ·	e all relationships with manufacturers of antihypertensive
me	dication, even if that medic	cation is not mentioned in	the manuscript.
		• •	ed in this manuscript without time limit. For all other items,
the	time frame for disclosure i	s the past 36 months.	
		A) II (5) 51	0 15 11 10
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
		Time frame: Since the initia	ar planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
)	Grants or contracts from	X None	
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
	,		

Consulting fees

X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	x	
	, , , , , , , , , , , , , , , , , , ,		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNOTIE	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dاح	ease summarize the above co	onflict of interest in the fol	lowing hox:
ric	.asc sammanze the above to		ioming box.
	None.		

	te: Mar. 3 <sup>rd</sup> , 2022 ur Name: Liu Liu	-	
Ma	anuscript Title: Inhibit	-	cdown on cellular functions of liver cancer stem cells
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a o so.
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	x	
	, , , , , , , , , , , , , , , , , , ,		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNOTIE	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dاح	ease summarize the above co	onflict of interest in the fol	lowing hox:
ric	.asc sammanze the above to		ioming box.
	None.		

	te: Mar. 3 <sup>-r</sup> , 2022 ur Name: Xiao Li Zhang _		
			down on cellular functions of liver cancer stem cells
Ma	nuscript number (if known)	: TCR-22-298_	
rel pa to rel The ma	ated to the content of your ries whose interests may be transparency and does not eationship/activity/interest, e following questions apply muscript only.  e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" me e affected by the content of necessarily indicate a bias it is preferable that you do to the author's relationsh ivities/interests should be ension, you should declare eation is not mentioned in	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	Il planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X\_\_None

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	x	
	, , , , , , , , , , , , , , , , , , ,		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNOTIE	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dاح	ease summarize the above co	onflict of interest in the fol	lowing hox:
ric	.asc sammanze the above to		ioming box.
	None.		

	te: Mar. 3 <sup>-r</sup> , 2022 ur Name: Qiu Luo Cheng		
		<del></del>	down on cellular functions of liver cancer stem cells
	anuscript number (if known)		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to	•	ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i	• •	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X\_\_None

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	x	
	, , , , , , , , , , , , , , , , , , ,		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNOTIE	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dاح	ease summarize the above co	onflict of interest in the fol	lowing hox:
ric	.asc sammanze the above to		ioming box.
	None.		

Da	te: Mar. 3 <sup>rd</sup> , 2022	_	
	ur Name: Ying Zhu		
			down on cellular functions of liver cancer stem cells
Ma	anuscript number (if known)	: TCR-22-298_	
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act the epidemiology of hypertedication, even if that medication item #1 below, report all support and the support and the support and support support and support and support support and support suppo	manuscript. "Related" me e affected by the content on necessarily indicate a bias it is preferable that you do to the author's relationshi ivities/interests should be ension, you should declare cation is not mentioned in	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
the	e time frame for disclosure i	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

4

X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	x	
	, , , , , , , , , , , , , , , , , , ,		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNOTIE	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dاح	ease summarize the above co	onflict of interest in the fol	lowing hox:
ric	.asc sammanze the above to		ioming box.
	None.		